Neoplasms

Rare Cancers Market: Analyzing trends in the Soft Tissue Sarcoma Market, Synovial Sarcoma Market, Glioblastoma Multiforme Market, Cholangiocarcinoma Market and Multiple Myeloma Market | DelveInsight

Retrieved on: 
Thursday, March 4, 2021
Sarcoma, Anatomical pathology, Neoplasms, Soft-tissue sarcoma, Cancer, Branches of biology, Clinical medicine, Oncology

The US National Cancer Institute defines rare cancers as those with an incidence of less than 15 cases per 100000 per year.

Key Points: 
  • The US National Cancer Institute defines rare cancers as those with an incidence of less than 15 cases per 100000 per year.
  • Lack of clinical expertise, research, and funding are other barriers in the Rare cancer market.
  • Therefore, the Rare cancer market calls for continued efforts to speed up the process of drug development.
  • DelveInisght expects an increase in the Soft tissue sarcoma market size during the study period, 20172030 at a CAGR of 6.47% in the 7MM.

Rare Cancers Market: Analyzing trends in the Soft Tissue Sarcoma Market, Synovial Sarcoma Market, Glioblastoma Multiforme Market, Cholangiocarcinoma Market and Multiple Myeloma Market | DelveInsight

Retrieved on: 
Thursday, March 4, 2021
Sarcoma, Anatomical pathology, Neoplasms, Soft-tissue sarcoma, Cancer, Branches of biology, Clinical medicine, Oncology

The US National Cancer Institute defines rare cancers as those with an incidence of less than 15 cases per 100000 per year.

Key Points: 
  • The US National Cancer Institute defines rare cancers as those with an incidence of less than 15 cases per 100000 per year.
  • Lack of clinical expertise, research, and funding are other barriers in the Rare cancer market.
  • Therefore, the Rare cancer market calls for continued efforts to speed up the process of drug development.
  • DelveInisght expects an increase in the Soft tissue sarcoma market size during the study period, 20172030 at a CAGR of 6.47% in the 7MM.

Synovial Sarcoma Market to Exhibit a CAGR of 16.14% During the Forecast Period of 2018-2030, States DelveInsight

Retrieved on: 
Wednesday, March 3, 2021
Sarcoma, Clinical medicine, Cancer, Neoplasms, Synovial sarcoma, Chemotherapy, Synovial fluid, Soft-tissue sarcoma

The Synovial Sarcoma market report also proffers an analysis of the current and emerging Synovial Sarcoma treatment landscape, market drivers, market barriers, and unmet medical needs.

Key Points: 
  • The Synovial Sarcoma market report also proffers an analysis of the current and emerging Synovial Sarcoma treatment landscape, market drivers, market barriers, and unmet medical needs.
  • As Synovial Sarcoma is a chemo-sensitive tumor, the first-line treatment includes single-agent or combination chemotherapy.
  • Doxorubicin with or without ifosfamide remains the mainstay of first-line chemotherapy for Synovial Sarcoma treatment.
  • The Synovial Sarcoma Market Report provides historical as well as forecasted epidemiological analysis segmented into:

SHEPHERD Therapeutics and Mayo Clinic Announce Collaboration to Advance Research in Rhabdomyosarcoma Using SHEPHERD's Precision-Oncology Platform, DELVE

Retrieved on: 
Thursday, February 25, 2021
Anatomical pathology, Sarcoma, Branches of biology, Neoplasms, Rhabdomyosarcoma, Oncology, Cancer

BOSTON, Feb. 25, 2021 /PRNewswire/ -- SHEPHERD Therapeutics , a company dedicated to catalyzing lifesaving treatments for rare cancer patients, today announced a collaboration with the Mayo Clinic to advance research in rhabdomyosarcoma (RMS), a rare pediatric cancer with few treatment options.

Key Points: 
  • BOSTON, Feb. 25, 2021 /PRNewswire/ -- SHEPHERD Therapeutics , a company dedicated to catalyzing lifesaving treatments for rare cancer patients, today announced a collaboration with the Mayo Clinic to advance research in rhabdomyosarcoma (RMS), a rare pediatric cancer with few treatment options.
  • Our collaboration with SHEPHERD Therapeutics and access to the DELVE platform represents a unique opportunity to extrapolate from more heavily-studied cancers and accelerate rhabdomyosarcoma research.
  • The SHEPHERD Foundation is a non-profit fighting to generate industry-wide change related to rare cancer awareness and therapeutic availability.
  • DELVE is SHEPHERD's next-generation, precision-oncology platform that integrates bioinformatics, machine learning, and mathematics to unveil unprecedented insights into cancer.

Salarius Pharmaceuticals Initiates Expansion Stage of Phase 1/2 Clinical Trial of Seclidemstat in Patients with Ewing Sarcoma and Ewing-Related Sarcomas

Retrieved on: 
Wednesday, February 24, 2021
Anatomical pathology, Sarcoma, Ewing's sarcoma, Neoplasms, Cancer, Clinical medicine

The second arm will enroll up to 30 patients with Ewing-related sarcomas and will investigate seclidemstat as a single-agent therapy at the RP2D.

Key Points: 
  • The second arm will enroll up to 30 patients with Ewing-related sarcomas and will investigate seclidemstat as a single-agent therapy at the RP2D.
  • Nadeem Q. Mirza, M.D., M.P.H., Senior Vice President, Clinical Development for Salarius, commented, There is strong support for this development strategy.
  • Dr. Mirza continued, The expansion into Ewing-related sarcomas is supported by encouraging signs of seclidemstat clinical activity among the subset of Ewing-related sarcoma patients enrolled in our Advanced Solid Tumor trial.
  • ET, to discuss advancements in the Phase 1/2 clinical trial of seclidemstat in patients with Ewing sarcoma and Ewing-related sarcomas.

Elicio Therapeutics Announces FDA Clearance of IND application for ELI-002-- A Therapeutic Vaccine Targeting mutated KRAS Cancers

Retrieved on: 
Tuesday, February 23, 2021
KRAS, Gastrointestinal cancer, Cancer, Pancreatic cancer, PDAC, Adenocarcinoma, Ras GTPase, Neoplasms

ELI-002 is an Amphiphile (AMP) KRAS therapeutic vaccine containing AMP mKRAS peptides and a proprietary AMP CpG adjuvant, administered subcutaneously.

Key Points: 
  • ELI-002 is an Amphiphile (AMP) KRAS therapeutic vaccine containing AMP mKRAS peptides and a proprietary AMP CpG adjuvant, administered subcutaneously.
  • The company's novel therapeutic vaccine targets KRAS mutations that drive 99% of all KRAS-driven cancers.
  • Phase I/II clinical trials of ELI-002 will enroll patients with mKRAS+ pancreatic ductal adenocarcinoma (PDAC) and other solid tumors.
  • Elicio's lead Amphiphile vaccine, ELI-002, targeting KRAS-driven cancers will begin initial patient studies in solid tumor patients in the first quarter of 2021.

Natera and Personalis Partner for Personalized Monitoring in Oncology

Retrieved on: 
Wednesday, February 17, 2021
Biotechnology, Pharmaceutical, Health, Oncology, Branches of biology, Clinical medicine, Medicine, DNA, Anatomical pathology, Circulating tumor DNA, Neoplasms, Oncology, Exome, Assay, Natera, Personalis

The partnership will pair Personalis NeXT tumor profiling and diagnostic products with Nateras personalized ctDNA platform Signatera for treatment monitoring and molecular residual disease (MRD) assessment.

Key Points: 
  • The partnership will pair Personalis NeXT tumor profiling and diagnostic products with Nateras personalized ctDNA platform Signatera for treatment monitoring and molecular residual disease (MRD) assessment.
  • Under this non-exclusive agreement, Natera will validate the design of Signatera personalized ctDNA assays using matched tumor and normal exome sequence data from Personalis, and Natera will be responsible for commercialization.
  • We are pleased to partner with them and to expand access of Signatera to a new set of potential customers.
  • We are excited to partner with Natera on this sensitive tumor-informed approach to accelerate molecular residual disease detection in cancer.

United States Soft Tissue Sarcoma Market and Competitive Landscape Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, February 17, 2021
Biotechnology, Pharmaceutical, Health, Neoplasms, Branches of biology, Soft-tissue sarcoma, Sarcoma, Soft tissue, Clinical medicine

The "US Soft Tissue Sarcoma Market and Competitive Landscape - 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "US Soft Tissue Sarcoma Market and Competitive Landscape - 2021" report has been added to ResearchAndMarkets.com's offering.
  • US Soft Tissue Sarcoma Market and Competitive Landscape Highlights - 2021, provides comprehensive insights into Soft Tissue Sarcoma pipeline products, Soft Tissue Sarcoma epidemiology, Soft Tissue Sarcoma market valuations and forecast, Soft Tissue Sarcoma drugs sales and competitive landscape in the US.
  • Soft Tissue Sarcoma pipeline: Find out the products in clinical trials for the treatment of Soft Tissue Sarcoma by development phase 3, phase 2, and phase 1, by pharmacological class and companies developing the products
    Soft Tissue Sarcoma drugs: Identify key products marketed and prescribed for Soft Tissue Sarcoma in the US, including trade name, molecule name, and company
    Soft Tissue Sarcoma drugs sales: Find out the sales revenues of Soft Tissue Sarcoma drugs in the US
    Soft Tissue Sarcoma market valuations: Find out the market size for Soft Tissue Sarcoma drugs in 2019 in the US.
  • Find out how the market advanced from 2017 and forecast to 2026
    Soft Tissue Sarcoma drugs market share: Find out the market shares for key Soft Tissue Sarcoma drugs in the US
    Evaluate commercial market opportunity assessment, positioning, and segmentation for Soft Tissue Sarcoma products
    View source version on businesswire.com: https://www.businesswire.com/news/home/20210217005475/en/

Professor Juan Marchal Believes Propanc Biopharma’s Proenzyme Therapy May Offer New Treatment Opportunity for Cancer Patients

Retrieved on: 
Monday, February 15, 2021
Research, Pharmaceutical, Oncology, Hospitals, Genetics, Clinical trials, Science, Surgery, Biotechnology, FDA, Other Science, Health, Cancer, Treatment of cancer, Causes of death, Prostate cancer, Health, Gastrointestinal cancer, Infectious causes of cancer, Neoplasms, Professor Juan Marchal, Propanc Biopharma, Inc.

This is particularly significant, since the incidence of metastasis greatly reduces the life expectancy of cancer patients.

Key Points: 
  • This is particularly significant, since the incidence of metastasis greatly reduces the life expectancy of cancer patients.
  • Searching for new cancer treatments to achieve a definitive cure for cancer patients is my motivation.
  • I am very excited to see what our therapy can do for cancer patients in future clinical studies.
  • Prof Juan Antonio Marchal, M.D, Ph.D., is a Professor of Human Anatomy and Embryology (Faculty of Medicine) at the University of Granada.

Gene-Based Blood Test for Melanoma Spread Evaluates Treatment Progress

Retrieved on: 
Friday, February 12, 2021
Medicine, Clinical medicine, Health, DNA, Oncology, Anatomical pathology, Circulating tumor DNA, Neoplasms, Melanoma, Cancer

"The blood test results could help support continuing the current treatment strategy or else encourage patients and physicians to consider other options," adds Polsky, the Alfred W. Kopf, M.D.

Key Points: 
  • "The blood test results could help support continuing the current treatment strategy or else encourage patients and physicians to consider other options," adds Polsky, the Alfred W. Kopf, M.D.
  • Early feedback from a blood test might save lives, he says.
  • In previous small studies, the blood test was shown to outperform LDH in predicting melanoma recurrence, as well as tracking progression of other forms of cancer.
  • The investigators say the blood test is highly reliable, as they were able to detect ctDNA in 93 percent of patients.